This is the published version of a paper published in *ESC Heart Failure*.

Citation for the original published paper (version of record):

Jonsson, A., Viklund, I., Jonsson, A., Valham, F., Bergdahl, E. et al. (2020) Comparison of creatinine-based methods for estimating glomerular filtration rate in patients with heart failure. *ESC Heart Failure, 7*(3): 1150-1160

https://doi.org/10.1002/ehf2.12643

Access to the published version may require subscription.

N.B. When citing this work, cite the original published paper.

Permanent link to this version:

http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-168959
Comparison of creatinine-based methods for estimating glomerular filtration rate in patients with heart failure

Anna Jonsson¹, Ida Viklund², Andreas Jonsson¹, Fredrik Valham¹, Ellinor Bergdahl¹, Krister Lindmark¹ and Helena Norberg¹,3*  
¹Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; ²Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden; ³Department of Integrative Medical Biology, Umeå University, Umeå, Sweden

Abstract

Aims Glomerular filtration rate is an important factor in management of heart failure (HF). Our objective was to validate eight creatinine-based equations for estimating glomerular filtration rate (eGFR) in an HF population against measured glomerular filtration rate.

Methods and results One hundred forty-six HF patients (mean age 68 ± 13 years, mean left ventricular ejection fraction 45% ± 15) within a single-centre hospital that underwent ⁵¹Cr-EDTA clearance between 2010 and 2018 were included in this retrospective study. eGFR was estimated by means of Cockcroft–Gault ideal and actual weight, the Modification of Diet in Renal Disease Study (MDRD), simplified MDRD with isotope dilution mass spectroscopy traceable calibration, the Chronic Kidney Disease Epidemiology Collaboration, revised Lund–Malmö, full age spectrum, and the Berlin Initiative Study 1. Mean measured glomerular filtration rate was 42 mL/min/1.73 m². Pearson’s correlation coefficient (r) had the highest precision for MDRD (r = 0.9), followed by revised Lund–Malmö (r = 0.88). All equations except MDRD (mean difference −4.8%) resulted in an overestimation of the renal function. The accuracy was below 75% for all equations except MDRD.

Conclusions None of the exclusively creatinine-based methods was accurate in predicting eGFR in HF patients. Our findings suggest that more accurate methods are needed for determining eGFR in patients with HF.

Keywords Heart failure; Renal function; Estimated glomerular filtration rate; Creatinine

Introduction

Impaired renal function is common in heart failure (HF). It is a major cause for withdrawal of treatment, prevents the initiation of pharmacological therapy in HF, and is associated with higher morbidity and mortality. Several creatinine-based equations have been developed for estimating glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD) and/or for the general population. However, a majority of these equations have not been validated for patients with HF. In HF, several factors are influencing the precision and accuracy of creatinine-based eGFR equations. Loss of muscle mass due to inactivity causes low creatinine levels, and fluid excess causes weight gain without an increase in lean body mass.

The cornerstones in treating HF with reduced ejection fraction are renin–angiotensin–aldosterone system inhibitors (RAAS-I), including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, as well as beta-blockers and mineralocorticoid receptor antagonists (MRAs). If a patient still has symptomatic HF and ejection fraction <35%, angiotensin receptor–neprilysin inhibitor should replace the RAAS-I. However, registry studies have shown that patients with HF fail to receive full treatment. RAAS-I and beta-blockers are prescribed to a high extent, but MRA treatment is underutilized, and one of the most common causes of
contraindication is impaired renal function.\(^5\) According to the European guidelines, an eGFR below 25 or 30 mL/min/1.73 m\(^2\) should cause dose reduction of RAAS-I and MRA, respectively, if on treatment.\(^4\) In clinical practice and randomized controlled trials, such as EMPHASIS and RALES, an eGFR below 30 mL/min/1.73 m\(^2\) and serum creatinine (s-creatinine) over 221 μmol/L respectively is an exclusion criterion for initiating MRA. Hence, estimating GFR correctly within the range of 20–40 mL/min/1.73 m\(^2\) is important because it can decide whether or not a patient with HF will be treated with RAAS-I and MRA.

Measurements of GFR by means of quantitative methods require plasma clearance of an exogenous marker. Plasma clearance of chromium-51-ethylenediaminetetraacetic acid (\(^{51}\)Cr-EDTA) is comparable with other gold standard methods.\(^6\) However, because this method for measured GFR (mGFR) is complex, expensive, and time-consuming to conduct on a routine basis in a large number of patients, eGFR based on creatinine or cystatin C is preferred in clinical practice. Creatinine-based eGFR is the most widely used method because of its lower costs but requires adjustment for demographic and anthropometric data that alter creatinine such as sex, age, and weight. Various equations for eGFR have been developed in order to make these adjustments. Currently, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), the Modification of Diet in Renal Disease Study (MDRD), and the revised Lund–Malmö (LM-rev) are recommended in international guidelines and national assessments.\(^7,8\) MDRD was developed for patients with CKD and requires serum-urea (s-urea) and serum-albumin (s-albumin).\(^9\) The simplified MDRD isotope dilution mass spectroscopy traceable calibration (sMDRD-IDMS) excludes s-urea and s-albumin, in order to make the equation more generalizable and has been re-expressed for standardized s-creatinine as sMDRDS-IDMS.\(^10\) CKD-EPI was developed for patients with GFR above 60 mL/min/1.73 m\(^2\) and has better accuracy than MDRD for patients without CKD.\(^11\) Three of the most recently developed equations are the LM-rev, the Berlin Initiative Study 1 (BIS1), and full age spectrum (FAS).\(^12–14\) LM-rev was developed in a Swedish cohort with a wide range of age, body mass index, and GFR levels. BIS1 is the only equation validated in an elderly population (70 years or older), while FAS is the only equation that has a continuity with aging, overcoming the problem of eGFR changes when otherwise switching between age-specific equations. Compared with these modern equations that were developed based on gold standard methods for mGFR, the Cockcroft–Gault actual weight (CG-AW) equation is based on creatinine clearance, and the CG and MDRD are the only equations not calibrated to a standardized IDMS-traceable s-creatinine method.\(^15\) CG ideal weight (CG-IW) is recommended by Cockcroft and Gault to be used on patients with potential volume overload.\(^15\)

The overall aim of this study was to assess the accuracy of these different equations for eGFR in patients with HF by comparing the predicted eGFR with \(^{51}\)Cr-EDTA measurements. By identifying the most accurate equation, we hope to optimize pharmacological treatment for patients with HF.

Methods

Study population

All patients who had at least one contact with the Heart Centre or Department of Internal Medicine at Umeå University Hospital, Sweden, between 2010 and 2018 and had received a diagnosis of HF (International Classification of Diseases codes I50.X, I42.0, I42.6, I42.7, I42.9, I11.0, I13.0, and I13.2) were examined for inclusion in this retrospective study. Of these, all patients who underwent plasma clearance with \(^{51}\)Cr-EDTA between 2010 and 2018 were identified. Additional data required for the equations were collected from the medical records. Values of s-creatinine, s-urea, and s-albumin were recorded as close as possible to the time of the \(^{51}\)Cr-EDTA measurements. Data for length and weight were collected from the \(^{51}\)Cr-EDTA measurements.

Measurement of renal function with \(^{51}\)Cr-EDTA

Plasma clearance of \(^{51}\)Cr-EDTA was measured for all patients at Umeå University Hospital. A pretest blood sample of 5 mL was drawn, and the activity of any radioactively substance was controlled. A single injection of 3.6 mL (1.03 MBq/mL of \(^{51}\)Cr-EDTA) was given. After attaining stable plasma levels, series of 8 mL blood samples were taken 180, 210, 240, and 270 min after the primary injection. An additional blood sample was taken after 24 h if s-creatinine exceeded 200 μmol/L or if GFR was calculated below 30 mL/min/1.73 m\(^2\). This method has an intra-individual day-to-day variance of 4 mL/min/1.73 m\(^2\) (coefficient of variance 6.25%). mGFR was corrected for body surface area (BSA) according to Haycock et al. (BSA = 0.024265 × Weight\(^{0.5378}\) × Height\(^{0.3964}\)). \(^{51}\)Cr-EDTA plasma clearance was calculated according to Bröchner–Mortensen by final slope.

Creatinine-based estimated glomerular filtration rate equations

Plasma creatinine (μmol/L) was analysed consecutively with the IDMS-traceable Roche enzymatic method CREP2 on Cobas c701 analysers in the ISO 15189 accredited laboratory at Umeå University Hospital.

ESC Heart Failure 2020; 7: 1150–1160
DOI: 10.1002/ehf2.12643
Eight equations were used for creatinine-based eGFR:

1. CG-AW (mL/min/1.73 m²) normalized to BSA 1.73m²:
   \[\text{BSA} = \text{weight}^{0.425} \times \text{height}^{0.725} \times 0.007184.\]

2. CG-IW (mL/min/1.73 m²) see Equation (1) where weight is IW except if actual body weight was lower than IW.

3. MDRD (mL/min/1.73 m²) = 170 \times (Scr/88.4)^{-0.99}
   \times \text{age}^{-0.176} \times (s\text{-urea} \times 18 \text{ mg/dL})^{-0.70}
   \times (s\text{-albumin}/10)^{-0.318} \times 0.76 \text{ if female}

4. sMDRD-IDMS (mL/min/1.73 m²) = 175
   \times (Scr/88.4)^{-1.154} \times \text{age}^{-0.203} \times 0.742 \text{ if female}

5. CKD-EPI for Caucasians (mL/min/1.73 m²) =
   (Female and Scr ≤ 62) 144 \times (Scr/(0.7 \times 88.4))^{-0.329}
   \times 0.993^{\text{age}}
   \times \text{age} + 0.438 \times \text{ln (age)}
   \times (\text{Male and Scr} \leq 80) 141 \times (Scr/(0.9 \times 88.4))^{-0.411}
   \times 0.993^{\text{age}} \times \text{age} + 0.438 \times \text{ln (age)}
   \times (\text{Male and Scr} > 80) 141 \times (Scr/(0.9 \times 88.4))^{-0.411}
   \times 0.993^{\text{age}} \times \text{age} + 0.438 \times \text{ln (age)}

6. LM-rev (mL/min/1.73 m²) = e^x - 0.0158
   \times \text{age} + 0.438 \times \text{ln (age)}
   \times \text{Male and Scr} < 180 \text{ mmol/L: } X = 2.56
   + 0.00968 \times (180 - \text{Scr})
   \times \text{Male and Scr} ≥ 180 \text{ mmol/L: } X = 2.56
   - 0.926 \times \text{ln (Scr/180)}
   \times (\text{Female and Scr} < 150 \text{ mmol/L: })
   \times X = 2.50 + 0.0121 \times (150 - \text{Scr})
   \times (\text{Female and Scr} ≥ 150 \text{ mmol/L: })
   \times X = 2.50 - 0.926 \times \text{ln (Scr/150)}

7. FAS (mL/min/1.73 m²) =
   \text{(Age 2 to ≤40 years) } 107.3/\text{Scr/Q}
   \text{(Age >40 years) } 107.3/\text{Scr/Q} \times 0.98^{\text{age} - 40}
   \times Q = \text{male 18 years: } 75, \text{ male } ≥20 \text{ years: } 80
   \times \text{female 18 years: } 61, \text{ female } ≥20 \text{ years: } 62

8. BIS1 (mL/min/1.73 m²) = 3736 \times (Scr/88.4)^{-0.87}
   \times \text{age}^{-0.395} \times 0.82 \text{ if female}
   \times \text{Scr} = \text{serum creatinine. Weight was measured in}
   \text{kilograms, height in centimetres, and age in years.}
   \text{Ethnicity was not recorded in this database, and all}
   \text{patients were assumed to be non-Black. Creatinine was}
   \text{divided by 88.4 for use with μmol/L. BSA was calculated}
   \text{with Du Bois method and ideal weight with Lemmens}
   \text{formula.}

Statistical analysis

For patient characteristic data, categorical variables are presented with frequencies and percentage and analysed with Pearson’s \( \chi^2 \) test. Continuous variables without normal distribution are presented as medians with inter-quartile range and analysed with Mann–Whitney U test. Continuous variables are presented as means with standard deviations and analysed with Student’s t-test. A P value less than 0.05 was considered statistically significant.

Tests for agreement were performed on eight different equations for eGFR. Pearson’s correlation coefficient (r) and Bland–Altman plots evaluated precision and bias respectively between measured GFR and each method for eGFR. The precision was considered acceptable if \( r \geq 0.8 \). The accuracy was defined as the percentage of patients with estimated GFR within ±30% of measured GFR (P30), calculated as [eGFR - mGFR]/100/mGFR, and considered acceptable if ≥75% of the eGFR was within ±30% of mGFR. McNemar test was performed for all equations to compare proportion of patients that were falsely divided into wrong eGFR group compared with mGFR, when sorted into groups of under or above GFR 30 mL/min/1.73 m². All analyses were performed in SPSS Version 25.

Ethics

This study complies with the Declaration of Helsinki. The Regional Ethical Review Board in Umeå, Sweden, has approved the study (Registration Number 2015/419-31).

Results

Out of 4450 patients in the total HF population, 146 patients (3%) had undergone a \(^{51}\text{Cr-EDTA} \) measurement. Among included patients, the mean left ventricular ejection fraction (±SD) was 47% ± 14, the mean age was 70 ± 14 years, and 57% were male; 33% of these had HF with reduced ejection fraction, 20% with mid-range ejection fraction (HFmrEF), and 47% with preserved ejection fraction (HFpEF). Comparing the patient characteristics of the study group with the total HF population, the study group was younger but had a similar left ventricular ejection fraction, while N-terminal pro-B-type natriuretic peptide was significantly higher. Furthermore, diabetes was more common, and s-creatinine was higher in the study group (Table 1).

In the study group, the mean mGFR was 42 mL/min/1.73 m², while mean eGFR was 30–59 mL/min/1.73 m² for all equations except MDRD (Figure 1). The reasons for conducting \(^{51}\text{Cr-EDTA} \) were CKD (33%), heart/lung/renal transplantation (29%), and malignancy (37%). All mGFR was...
conducted before start-up of cytostatic drugs. Seven patients conducted mGFR before the transplantation, and among the renal transplanted, all patients had conducted mGFR after transplantation. Mean mGFR for the renal transplanted was 29 mL/min/1.73 m², and the majority have their transplantation performed several years before conducting mGFR, why the values were relatively stable. MDRD included 69 patients (47%) with a mean eGFR of 28 mL/min/1.73 m², as s-urea and s-albumin were mainly available for patients with impaired renal function. BIS1 was applied on patients 70 years or older and included 71 patients (49%).
Eighty-five per cent of the s-creatinine values and 81% of the s-albumin and s-urea values were measured within ±14 days from the \(^{51}\text{Cr}-\text{EDTA}\) measurement, and 96% of the s-creatinine values were measured within ±30 days.

The equation with the highest precision was MDRD. LM-rev showed almost as high precision as MDRD (Figure 2). Bland–Altman plots showed that MDRD was the only equation to underestimate the renal function while all remaining equations overestimated the eGFR (Figure 3). Furthermore, MDRD had superior accuracy as 80% had an eGFR within ±30% of measured GFR, while all the remaining equations fell under the 75% cut-off (Figure 4). Among the creatinine-based equations, LM-rev and CG-IW both had the lowest overestimation, with a mean difference of 18%, but LM-rev showed higher accuracy. One of the most commonly used equation, CKD-EPI, showed a wide variation of eGFR values in HF patients with low precision and accuracy. All equations except the MDRD falsely categorize patients that have an actual GFR under 30 mL/min/1.73 m\(^2\), thus overestimating GFR when compared with mGFR (Figure 2).

Mean age was comparable when categorizing the study group into subgroups, but in the HFpEF group, a majority of the patients were female and had higher creatinine levels compared with the other subgroups (Supporting Information, Table S1). Furthermore, CG-IW was more accurate in patients with HF with reduced ejection fraction and HFmrEF than the whole study group. BIS1 had slightly better results in patients with HFpEF, and LM-rev showed better results in patients with HFmrEF and HFpEF compared with the whole study group, while MDRD had consistently good results in all subgroups (Table 2).

Discussion

A majority of HF patients suffer from impaired renal function,\(^{16}\) and while many attempts have been made to find the best creatinine-based equation to estimate GFR, most of the equations have not been validated before in an HF population. In this study, we evaluated bias, precision, and accuracy of eight creatinine-based equations for eGFR in a wide range of HF patients, with both reduced and preserved ejection fraction. In subgroup analyses of the different HF classes, the result was consistent with the whole study group. The results indicate that none of the exclusively creatinine-based methods had a high accuracy or precision in predicting GFR. Nevertheless, even with mGFR, there are methodological issues and imprecisions, and results from EDTA measurements and inulin clearance, which is the historical gold standard, may differ considerably.

Revised Lund–Malmö, BIS1, FAS, and sMDRD-IDMS have to our knowledge not previously been externally validated in HF patients.\(^{16–20}\) In this study, none of the exclusively creatinine-based eGFR equations met the criteria of accuracy, precision, and a non-significant McNemar test. Furthermore, all creatinine-based eGFR equations led to an overestimation of the renal function. Therefore, we concluded that none of the exclusively creatinine-based equations for eGFR were accurate for estimating GFR in this population of HF patients. In accordance with our findings, previous studies comparing creatinine-based equations in HF have shown an overestimation of eGFR at lower GFR values.\(^{18,19}\) In this study, MDRD was the only equation that did not overestimate GFR under 30 mL/min/1.73 m\(^2\).

Furthermore, MDRD was the most precise equation with the highest accuracy and lowest bias, but because both s-urea and s-albumin are required, the results in this study should only be generalizable to patients with both HF and CKD as all patients included in this group had a mean eGFR under 30 mL/min/1.73 m\(^2\) because s-urea and s-albumin only were available for patients with known CKD. Overestimation of eGFR in patients with HF could be due to a haemodynamically driven renal impairment.\(^{21}\) Reduced renal perfusion causes reduced filtration rate in the nephron, but the tubuli were still intact and able to secrete creatinine. Hence, creatinine levels are not built up in the blood as compared with primary renal disease where there is a loss of both glomeruli and corresponding tubuli. With the MDRD equation, it is possible that s-urea and s-albumin correct for the low creatinine levels in HF. Another factor contributing to overestimated GFR in HF is lower s-albumin due to physical inactivity leading to reduced muscle mass in this group of patients, causing cardiac cachexia.\(^{22}\) Impaired renal function is a known risk factor for morbidity and mortality in HF, implying that patients with impaired renal function to a further extent have more severe HF, thus more exaggerated muscle mass waste.

Among the exclusively creatinine-based equation, LM-rev was the most accurate equation. It had almost as high precision as MDRD but overestimated eGFR compared with mGFR and did not meet the criteria for significant accuracy. LM-rev was developed on a Swedish population with a substantial variability in mGFR, body mass index, and age, which could explain the better results when applied in our study group with similar demographic characteristics. Furthermore, LM-rev is based on an IDMS-traceable s-creatinine analysis. Only LM-rev, CKD-EPI, FAS, BIS1, and sMDRD-IDMS are based on the standardized IDMS-traceable methods as recommended.\(^{23}\) The commonly used CKD-EPI equation showed very low accuracy in this study. CKD-EPI was developed on patient with a higher mean mGFR than our study population. In this study, 80% of all included patients had an eGFR under 60 mL/min/1.73 m\(^2\) and more than a third had diabetes as well, implying that CKD-EPI was not suitable in this group of patients.

Cockcroft–Gault ideal weight had almost comparable results with LM-rev. CG-IW and CG actual weight were the only equations to include weight. When comparing the two methods to calculate CG, calculating the ideal body weight
Figure 2. Pearson’s correlation coefficient (r). For details, see Table 2. McNemar test with glomerular filtration rate 30 mL/min/1.73 m² limits (green lines): $P < 0.001$ for all tests except MDRD ($P = 0.727$).
rather than actual weight gave more accurate results. The difference could be explained by sodium retention leading to fluid excess and consequently falsely high weight in HF patients.\textsuperscript{22} Different methods were used to calculate BSA for CG actual weight and mGFR. BSA was already calculated according to Haycock \textit{et al.} by the local laboratory conducting the GFR measurement. To calculate CG actual weight we used the exact same equation from the original article by Cockcroft and Gault from 1976.\textsuperscript{15}

The findings of this study imply that the choice of equation for eGFR has an impact on the categorizing of patients into whether dose adjustments should be recommended or not. A majority of creatinine-based eGFR led to an overestimation of the renal function. Dose adjustment or discontinuation of

\textbf{Figure 3}  Bland–Altman scatterplots of the distribution of the true \textsuperscript{51}Cr-EDTA–measured GFR (mGFR) and each creatinine-based equation for estimated glomerular filtration rate. The y axis shows the mean differences in % and the x axis the average of the mGFR and estimated glomerular filtration rate. The lines represent the mean difference in % and the upper and lower limits of agreement. For details, see Table 2.
Figure 4  P30 for each creatinine-based equation for estimated glomerular filtration rate. P30 = the percentage of patients with estimated glomerular filtration rate within ±30% of measured glomerular filtration rate. The dotted line represents the 75% cut-off for acceptable accuracy. For details, see Table 2.

Table 2  Precision, mean difference, McNemar test, and accuracy for the study group and all subgroups

| Study group          | r    | Mean difference | P  | P30 (%) | HFrEF | r    | Mean difference | P  | P30 (%) |
|----------------------|------|-----------------|----|---------|-------|------|-----------------|----|---------|
| CG-AW                | 0.81 | 30 (32)         |    | 46      | CG-AW | 0.92 | 27.6 (32.0)     |    | 0.06 41 |
| CG-IW                | 0.85 | 18 (30)         |    | 63      | CG-IW | 0.92 | 16.4 (31.7)     |    | 0.22 62 |
| MDRD                 | 0.9  | -4.8 (27)       | 0.73| 80      | MDRD  | 0.85 | 0.74 (38.0)     |    | 1 75 |
| CKD-EPI              | 0.87 | 26 (27)         |    | 58      | CKD-EPI | 0.92 | 24.6 (31.1)     |    | 0.03 62 |
| LM-rev               | 0.88 | 18 (27)         |    | 68      | LM-rev | 0.93 | 17.4 (29.3)     |    | 0.13 69 |
| FAS                  | 0.86 | 24 (28)         |    | 55      | FAS   | 0.92 | 24.3 (30.2)     |    | 0.03 55 |
| BIS1                 | 0.87 | 21 (25)         |    | 59      | BIS1  | 0.94 | 17.6 (20.2)     |    | 0.25 69 |
| sMDRD-IDMS           | 0.87 | 26 (27)         |    | 56      | sMDRD-IDMS | 0.93 | 27.3 (29.7)     |    | 0.06 48 |
| HFrEF                |      |                 |    |         |       |      |                 |    |         |
| CG-AW                | 0.75 | 32.2 (32.4)     | 0.12| 52      | CG-AW | 0.8  | 29.0 (32.1)     |    | 0 44 |
| CG-IW                | 0.8  | 20.6 (32.4)     | 0.07| 71      | CG-IW | 0.86 | 16.2 (27.8)     |    | 0.11 59 |
| MDRD                 | 0.89 | -7.6 (25.2)     | 0.63| 77      | MDRD  | 0.89 | -5.0 (23.7)     |    | 1 83 |
| CKD-EPI              | 0.8  | 28.5 (29.0)     | 0.03| 56      | CKD-EPI | 0.9 | 23.8 (23.2)     |    | 0.01 57 |
| LM-rev               | 0.79 | 19.6 (29.6)     | 0.13| 71      | LM-rev | 0.91 | 16.3 (23.9)     |    | 0.29 65 |
| FAS                  | 0.79 | 27.1 (29.8)     | 0.07| 58      | FAS   | 0.89 | 22.5 (26.7)     |    | 0.01 54 |
| BIS1                 | 0.89 | 27.8 (25.0)     | 0.03| 50      | BIS1  | 0.86 | 17.6 (27.3)     |    | 0.13 61 |
| sMDRD-IDMS           | 0.79 | 28.9 (29.6)     | 0.01| 56      | sMDRD-IDMS | 0.9 | 23.4 (23.4)     |    | 0.01 59 |

BIS1, Berlin Initiative Study 1; CG, Cockcroft–Gault; CG-AW, Cockcroft–Gault actual weight; CG-IW, Cockcroft–Gault ideal weight; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; FAS, full age spectrum; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LM-rev, revised Lund–Malmö; MDRD, Modification of Diet in Renal Disease Study; sMDRD-IDMS, simplified MDRD corrected for traceable isotope dilution mass spectrometry.

r = Pearson’s correlation. Mean difference % (±1 SD). P = McNemar test (P < 0.05 = significant). P30 = accuracy [the percentage of patients with estimated glomerular filtration rate within ±30% of measured glomerular filtration rate (P30)].

ESC Heart Failure 2020; 7: 1150–1160
DOI: 10.1002/ehf2.12643
both RAAS-I and MRAs is recommended at eGFR below 20–30 mL/min/1.73 m² because there is a risk of exacerbated renal insufficiency if the doses exceed the therapeutic range. Previous major studies on congestive HF have used varying methods for estimation of renal function. Some studies such as SHIFT²⁴ and RALES²⁵ used a fixed exclusion cut-off s-creatinine level of more than 220 and 221 μmol/L, respectively. Calculating eGFR by the MDRD equation was used by the PARADIGM-HF²⁶ and EMPHASIS HF²⁷ trials. The CKD-EPI equation was used in the DAPA-HF²⁸ study. Creatinine clearance was estimated according to the CG formula in the EP-ESUS²⁹ trial. Considering the results of this study, it is likely to conclude that dose adjustment would be needed for many HF patients if eGFR was calculated with the same equation as the original study that the recommendation is based on. Furthermore, this may imply that there is an uncertainty in the guidelines³ for therapeutic management of HF patients with impaired renal function, because it is based on eGFR calculated with different equations or s-creatinine.

**Strengths and limitations**

We compared eight established equations for eGFR, which has not been performed before in HF patients. Our study is the largest study comparing mGFR with eGFR in HF patients. Because the study group consists of patients with both preserved and reduced ejection fraction compared with previous studies,¹⁸,¹⁹ it should make our study more representative for real-life HF patients.

A limitation of this study is the selection of HF patients. Because the patients were selected on International Classification of Diseases coding, there may have been some cases with HFrEF that were misdiagnosed. Furthermore, this retrospective study is based on patients where a clinical decision has been made to measure GFR. However, comparing patient characteristics between the study group and all HF patients showed similarity in almost all characteristics. Nevertheless, the study group had significantly higher median s-creatinine, higher frequency of diabetes, and lower mean age. The results of this study should therefore only be generalized on patients with both HF and a mild renal dysfunction. This study also lacks data on the oldest patient group. In designing future studies, efforts should be made to include this group because the oldest patients are such a large part of the HF population. The study group also had significantly higher s-creatinine than the total HF population causing a selection bias were included patient already had a reason for conducting mGFR in the first place. Furthermore, another limitation to the study is the time interval from conducting GFR measurement and collecting s-creatinine. Because of individual fluctuation in renal function, this could cause bias in comparing mGFR with eGFR because the difference could reflect an actual difference. However, the absolute vast majority (85%) had a maximum time interval of 14 days, and 96% had a time interval of 30 days from mGFR to s-creatinine.

Cystatin C-based equations are more accurate when estimating GFR. We were however not able to analyse these equations in this study, because we only had data available for eight patients.³⁰

**Conclusions**

Our findings implicate that none of the exclusively creatinine-based methods were accurate in predicting GFR in HF patients. However, MDRD was the most accurate equation for patients with both HF and renal failure. One of the most commonly used equations, CKD-EPI, was not very accurate in measuring eGFR in patients with HF. Our findings suggest that more accurate methods are needed for determining eGFR in patients with HF, as overestimation causes an unnecessary risk of serious adverse effect as well as may lead to patients not receiving an optimal drug therapy.

**Acknowledgements**

The authors thank all the personnel who obtained data for the study. We would like to thank Robert Lundquist, statistician at Norrbotten County Council, for his help with the statistical analysis.

**Conflict of interest**

None declared.

**Funding**

This work was supported by the Heart Foundation of Northern Sweden.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1.** Baseline characteristics of the study group and the heart failure subgroups.
References

1. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. Does the role of the kidney in heart failure. *Eur Heart J* 2012; 33: 2135–2142.

2. Maggioni AP, Anker SD, Dahlstrom U, Filipatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2013; 15: 1173–1184.

3. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, Van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13: 599–608.

4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano G, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016; 37: 2129–2200.

5. Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano G, Dahlstrom U, Lund LH. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11,215 patients from the Swedish Heart Failure Registry. *Eur J Heart Fail* 2018; 20: 1326–1334.

6. Hagstam KE, Nordenfelt I, Svensson L, Svensson SE. Comparison of different methods for determination of glomerular filtration rate in renal disease. Scand J Clin Lab Invest 1974; 34: 31–36.

7. Improving Global Outcomes CKDWG. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013; 3: 1–150.

8. Swedish Council on Health Technology A. Methods to Estimate and Measure Renal Function (Glomerular Filtration Rate): A Systematic Review. SBU Yellow Report No. 214. Stockholm: Swedish Council on Health Technology Assessment (SBU), 2013.

9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann Intern Med* 1999; 130: 461–470.

10. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, van Lente F, for Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem* 2007; 53: 766–772.

11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150: 604–612.

12. Bjork J, Grubb A, Sterner G, Nyman U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. *Scand J Clin Lab Invest* 2013; 71: 233–239.

13. Pottel H, Hoste L, Dubourg L, Ebert N, Schaeffner E, Eriksen BO, Melsom T, Lamb EJ, Rule AD, Turner ST, Glassock RJ, de Souza V, Sellstre L, Mariat C, Martens F, Delaney P. An estimated glomerular filtration rate equation for the full age spectrum. *Nephrol Dial Transplant* 2016; 31: 798–806.

14. Schaeffner ES, Ebert N, Delaney P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, Schuchardt M, Tölle M, Ziebig R, van der Giet M. Two novel equations to estimate kidney function in persons aged 70 years or older. *Ann Intern Med* 2012; 157: 471–481.

15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31–41.

16. Szummer K, Evans M, Carrero JJ, Alehagen U, Dahlstrom U, Benson L, Lund LH. Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft–Gault equation in patients with heart failure. *Open Heart* 2017; 4: e000568.

17. O’Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. *Eur J Heart Fail* 2006; 8: 63–67.

18. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. *Circulation* 2006; 114: 1572–1580.

19. Valente MA, Hillege HL, Navis G, Voors AA, Dunselman PH, van Veldhuisen DJ, Damman K. The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. *Eur J Heart Fail* 2014; 16: 86–94.

20. Liborio A, Uchoa R, Neto J, Valdivia J, Daher E, Mejia J. Assessing glomerular filtration rate in patients with severe heart failure: comparison between creatinine-based formulas. *São Paulo medical journal = Revista paulista de medicina* 2012; 130: 289–293.

21. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. *J Clin Invest* 1990; 39: 10–21 discussion 2–4.

22. Okoshi MP, Capalbo RV, Remeo FG, Okoshi K. Cardiac cachexia: perspectives for prevention and treatment. *Arq Bras Cardiol* 2017; 108: 74–80.

23. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. *Clin Chem* 2006; 52: 5–18.

24. Swedberg K, Komajda M, Bohm M, Borser JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I4 Inhibitor Ivabradine Trial (SHIFT). *Eur J Heart Fail* 2010; 12: 75–81.

25. Pitt B, Zannad F, Remme WJ, CODY R, CASTAIGNE A, Perez A, Palesy J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999; 341: 709–717.

26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial. *Eur Heart J* 2013; 34: 1–24.
Failure trial (PARADIGM-HF). *Eur J Heart Fail* 2013; 15: 1062–1073.

27. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011; 364: 11–21.

28. McMurray JJV, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M. A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). *Eur J Heart Fail* 2019; 21: 665–675.

29. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; 348: 1309–1321.

30. Damman K, van der Harst P, Smilde TD, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. *Heart* 2012; 98: 319–324.